HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk A/S


Latest From Novo Nordisk A/S

Corbus Keeps Rising On ADC And Obesity Plans

The company is on a roll thanks to its challenge to Pfizer’s Padcev and competition with a potential obesity market gamechanger from Novo Nordisk.

Clinical Trials Companies

Lotus Builds In Southeast Asia With Teva Thailand Acquisition

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

M & A Deals

Skye Bioscience Looks To Build Appetite For CB1 Obesity Drug

The company will take on Novo Nordisk in reviving the CB1 inhibitor mechanism to develop a more tolerable long-term weight loss drug, after exiting ophthalmology.

Companies Clinical Trials

Orphan Drugs – Slowdown Signals New Paths Ahead

Signs are that the rate of sales growth for orphan drugs is slowing but that does not mean that they have had their day. Far from it, finds a new report from Evaluate.

Innovation Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Carbometrics
    • Corvidia Therapeutics
    • Neose Technologies, Inc.
    • Novo Holdings A/S
    • Novo Nordisk Pharmaceuticals, Inc.
    • Pharmaero Aps
    • Xellia Pharmaceuticals ApS
    • Ziylo Ltd